Aurobindo Pharma files SEBI Takeover Regulation 31(4) disclosure

Regulatory 19 Jun 2026 · Filed / open· ✓ Verified

The filing is a mandatory disclosure to NSE (and typically BSE simultaneously) as per SEBI (SAST) Regulations 2011. Regulation 31(4) requires disclosure of changes in shareholding that cross prescribed thresholds. The specific acquiring party, shareholding percentage, consideration value, and any linked open offer mechanism are not disclosed in the available primary document excerpt.

Why it mattersRegulation 31(4) triggers upon crossing 5% or subsequent 2% shareholding thresholds; the disclosure signals either a substantial acquisition or a connected person's holding reaching a regulatory gate, requiring evaluation of open offer or exemption application mechanics.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals